EUKARYS

Eukarÿs develops synthetic gene therapies for severe liver disorders, as well as bioporduction tools for recombinant proteins and viruses, all based on the proprietary expression system C3P3

The French Biotechnology Company Eukarÿs SAS exploits the applications of its proprietary C3P3 platform technology, which is used for both therapeutic and non-therapeutic purposes. Its so-called synthetic gene therapy approach voir plus

The French Biotechnology Company Eukarÿs SAS exploits the applications of its proprietary C3P3 platform technology, which is used for both therapeutic and non-therapeutic purposes. Its so-called synthetic gene therapy approach based on its C3P3 system is radically different of those existing to date in terms of efficiency, safety of use, tolerance. Due to the generic and modular nature of synthetic gene therapy, Eukarÿs is building a therapeutic pipeline initially for severe liver diseases. The R&D phase of our first candidate therapy - EUK-LPR - for the prevention of hepatic insufficiency after major liver resection will be finalized T4 2018 with already excellent performances. In addition, Eukarÿs is developing non-therapeutic C3P3 tools for the bioproduction of recombinant proteins and lentiviruses with the aim of marketing them via non-exclusive licensing agreements. voir moins

Finances : capitaux et levées de fonds
Marché & secteur
Compétition secteur
8
Moy. France 4,8
Création secteur
10,9%
Moy. France 8,5%
Code Naf
7490B
Modèle
-
Maturité des startups du secteur
Startups à suivre
Startup Création
LUNEALE Avr. 2015
POPSI CUBE Juil. 2004
NANOSIVE Déc. 2017
SAFE Mar. 2013
MELLITECH Oct. 2005
STANIPHARM Déc. 2009
NOVIAN HEALTH Déc. 2011
O4CP 0000
DOMAIN THERAPEU Oct. 2001
ONATERA Fév. 2011
Fondateurs & team
Fondateurs
Fondateur Âge École Diplôme Compétences
Philippe Jais
CEO
61 The Johns Hopkins University Post-doc Genomics, Genetics, Biotechnology, Drug Development, Clinical Development,
janv. 2012 - Aujourd'hui
President & Chief Scientific Officer chez Eukarÿs SAS
janv. 2015 - Aujourd'hui
Membre du comité d investissement chez SATT Nord
oct. 2014 - aout 2017
Director of Clinical Research and Translational Medicine chez AzurRx BioPharma
Fondateurs & Team
Philippe Jais CEO
Localisation
Adresse
4 Rue Pierre Fontaine, 91000 Évry, France, 91000 Évry
Website
Réseaux sociaux
Startups du secteur par département Voir la liste »
Évol. Départements Startups
Paris 14
Rhône 7
Essonne 3
Hauts-de-Seine 3
Isère 3
Haute-Garonne 3
Maine-et-Loire 2
Hérault 2
Meurthe-et-Moselle 2
Loire-Atlantique 2
Legals & tech stack
Légales
Raison sociale
EUKARYS
Siret
52334458800026
Forme juridique
Société par action simplifiées
Code Naf
7490B
Dernier mouvement Bodacc
Changement de capital
Jan. 2021
Tech Stack
Analytics and Tracking
Hoverowl
Widgets
Chartspree
Content Management System
Web-Kare
Advertising
Tinkoff Datamind